Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Gains from Investment Securities: 2022-2025

Historic Gains from Investment Securities for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to $58,031.

  • bioAffinity Technologies' Gains from Investment Securities fell 36.26% to $58,031 in Q3 2025 from the same period last year, while for Sep 2025 it was $342,310, marking a year-over-year decrease of 0.69%. This contributed to the annual value of $361,181 for FY2024, which is 287.38% up from last year.
  • Latest data reveals that bioAffinity Technologies reported Gains from Investment Securities of $58,031 as of Q3 2025, which was down 37.58% from $92,975 recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Gains from Investment Securities ranged from a high of $1.1 million in Q1 2023 and a low of $1,786 during Q3 2022.
  • Over the past 3 years, bioAffinity Technologies' median Gains from Investment Securities value was $90,440 (recorded in 2024), while the average stood at $164,003.
  • Per our database at Business Quant, bioAffinity Technologies' Gains from Investment Securities surged by 50,849.51% in 2023 and then tumbled by 91.94% in 2024.
  • Over the past 4 years, bioAffinity Technologies' Gains from Investment Securities (Quarterly) stood at $26,692 in 2022, then spiked by 179.25% to $74,538 in 2023, then grew by 22.14% to $91,038 in 2024, then crashed by 36.26% to $58,031 in 2025.
  • Its Gains from Investment Securities stands at $58,031 for Q3 2025, versus $92,975 for Q2 2025 and $100,266 for Q1 2025.